Outlook Therapeutics Inc. (OTLK)
NASDAQ · Healthcare
Outlook Therapeutics Inc. EBITDA 2015–2025
Outlook Therapeutics Inc. annual/quarterly ebitda history and growth rate from 2015 to 2019. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- Outlook Therapeutics Inc. ebitda for the quarter ending June 30, 2019 was -4.8 M, a 24.81% decrease year-over-year.
- Outlook Therapeutics Inc. ebitda for the twelve months ending June 30, 2019 was -27.5 M, a 22.64% increase year-over-year.
- Outlook Therapeutics Inc. annual ebitda for 2025 was -66.9 M, a 103.25% increase from 2019.
- Outlook Therapeutics Inc. annual ebitda for 2019 was -32.9 M, a 23.87% increase from 2018.
- Outlook Therapeutics Inc. annual ebitda for 2018 was -26.6 M, a 19.88% decrease from 2017.
- Outlook Therapeutics Inc. annual ebitda for 2017 was -33.2 M.
EBITDA
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Outlook Therapeutics Inc. EBITDA — FAQ
Outlook Therapeutics Inc. (OTLK) ebitda over the last 6 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see OTLK's ebitda history?
The chart and table above show Outlook Therapeutics Inc.'s ebitda by year and by quarter, including the growth rate.